Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

French Trial Tragedy May Spark Change In EU Phase I Risk Assessments 

This article was originally published in SRA

Executive Summary

Drug regulators in the EU are looking closely at the way that Phase I studies are planned and designed amid calls for better protection for volunteers in the wake of the French BIA 10-2474 trial tragedy. Among topics likely to be under consideration are a more consistent approach to determining the potential risk of novel compounds, and greater use of sequential dosing in first-in-human clinical trials.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst